CClinicalTrials.gg
CompletedNCT04896151Updated Oct 5, 2023

Assessing the Utility of MMPI-2-RF-EX in Detecting Simulated Underreporting of Current Suicide Risk in Military Veterans

An interventional study of Minnesota Multiphasic Personality Inventory -2- Restructured Form - Experimental in Suicidal Ideation and Suicidal, sponsored by Ohio State University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-05.

Sponsored by Ohio State University · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the current project are is examine the incremental predictive utility of the MMPI-2-RF-EX validity scales in detecting simulated underreporting of suicide risk on the MMPI-2-RF-EX and other self-report measures of suicide risk in 150 military Veterans experiencing past-month death or suicidal ideation.

02

Conditions studied

  • Suicidal Ideation
  • Suicidal
03

In context

Suicide

701 studies on the registry are indexed under Suicide; 183 are open to participants now.

This study's enrollment of 75 is below the median of 104 across 560 interventional studies indexed under Suicide.

Browse Suicide studies →

Lead sponsor

Ohio State University is the lead sponsor of 640 studies on the registry; 144 are open to participants now.

Of its 60 completed or terminated interventional studies of FDA-regulated products, 45 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 18 years of age or older
  • US military veteran
  • death or suicidal ideation/suicide attempt within the past month

Exclusion criteria

Exclusion Criteria:

  • non-Veteran status
  • acute intoxication or active psychosis precluding provision of informed consent
  • an inability to communicate and comprehend English
  • residence outside the United States
  • lack of past-month death/suicide ideation or attempt
  • younger than 18 years of age
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Active comparator
    Standard MMPI

    Participants will be instructed to complete the MMPI-2-RF-EX and other measures under standard conditions (e.g., to not simulate underreporting of suicide risk).

    Diagnostic Test: Minnesota Multiphasic Personality Inventory -2- Restructured Form - Experimental

  • Experimental
    Simulation MMPI

    Participants will be instructed to conceal current suicide risk when completing the MMPI-2-RF-EX and other measures.

    Diagnostic Test: Minnesota Multiphasic Personality Inventory -2- Restructured Form - Experimental

Interventions

  • Diagnostic testMinnesota Multiphasic Personality Inventory -2- Restructured Form - Experimental

    The MMPI-2-RF-EX is a broadband, self-report measure of personality and psychopathology was developed for research purposes in order to develop the MMPI-3 (Ben-Porath \& Tellegen, 2020), which is comprised of a subset of MMPI-2-RF-EX items.

    Also known as: MMPI-2-RF-EX

06

What researchers measure

Primary outcomes

  1. MMPI-2-RF-EX Suicidal/Death Ideation scale

    The MMPI-2-RF-EX Suicidal/Death Ideation scale is a self-report measure of current suicide risk contained within the instrument. T scores range from 45 to 100, with higher scores indicative of greater suicide risk.

    Time frame: Baseline

  2. Beck Scale for Suicide Ideation (BSS)

    The BSS is a 21-item measure of past-week suicide ideation and desire for death. Responses to items are scored on a 3-point Likert scale (range of 0- 2). Scores range from 0 to 42, with higher scores indicating greater suicide risk.

    Time frame: Baseline

Secondary outcomes

  1. Suicide Cognitions Scale (SCS)

    The SCS is an 18-item survey measuring suicide-related thoughts and beliefs, unclouding hopelessness, perceived burdensomeness, entrapment, and unbearability. Respondents rate their agreement with each statement on a 5-point Likert scale. Scores range from 18-90, with higher scores indicating more severe suicide risk.

    Time frame: Baseline

Other outcomes

  1. Short Grit Scale

    The Short Grit Scale is an 8-item measure of trait-level perseverance and passion for long-term goals. Possible scores range from 5 to 40, with higher scores indicting higher levels of grit.

    Time frame: Baseline

  2. MMPI Posttest Inquiry (PTI)

    The PTI assesses participants' compliance with condition-specific instructions for completing the MMPI and was adapted for the proposed research

    Time frame: Baseline

  3. PTSD Checklist for DSM-5 (PCL-5) PTSD Checklist for DSM-5

    The PCL-5 is a self-report measure assessing the severity of 20 PTSD symptoms. Scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity.

    Time frame: Baseline

07

Study locations

1 site
  • The Ohio State University
    Columbus, Ohio 43214, United States
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Feb 25, 2021
  • Informed consent form · Feb 25, 2021

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04896151
Lead sponsor
Ohio State University
Collaborators
University of Minnesota, Rutgers University
Responsible party
Lauren Khazem (Principal Investigator, Ohio State University) — Principal investigator
First posted
May 21, 2021
Start date
May 15, 2021
Primary completion
Feb 14, 2023
Completion
Feb 14, 2023
Last update
Oct 5, 2023

Study contacts

Lauren Khazem, PhD
principal investigator · Ohio State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion